Linsitinib (OSI-906)

Name: Linsitinib (OSI-906)
Brand: Selleck Chemicals
SKU: S1091
Rating: 5 (114 reviews)

For research use only.

Catalog No.S1091

114 publications

CAS No. 867160-71-2

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Selleck's Linsitinib (OSI-906) has been cited by 114 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nature, 2016, 24;539(7630):570-574.

PubMed: 27820945 ( click the link to review the publication )

Cancer Cell, 2015,

PubMed: 25670080 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )

FASEB J, 2020, 34(4):5363-5388

PubMed: 32067272 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):920-926

PubMed: 31871269 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2020, 16;11:219

PubMed: 32373071 ( click the link to review the publication )

Oncol Rep, 2020, 44(4):1649-1661

PubMed: 32945502 ( click the link to review the publication )

Biol Pharm Bull, 2020, 10.1248/bpb.b20-00362

PubMed: 32863294 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(1):186-194

PubMed: 31993315 ( click the link to review the publication )

Nat Commun, 2019, 10(1):518

PubMed: 30705270 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )
Aging Cell, 2019, 18(3):e12932

PubMed: 30884121 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32668

PubMed: 31490549 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

FASEB J, 2019, 33(10):11210-11222

PubMed: 31291762 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

J Gerontol A Biol Sci Med Sci, 2019, 74(9):1375-1385

PubMed: 30329021 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:5497467

PubMed: 31467485 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1777

PubMed: 29725014 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2546

PubMed: 29959327 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Genes Dev, 2018, 32(13-14):915-928

PubMed: 29945888 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Mol Cancer, 2018,

PubMed: 29455661 ( click the link to review the publication )
Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Oncotarget, 2018, 9(10):8810-8822

PubMed: 29507656 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29416603 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4014-4025

PubMed: 28619711 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 28534511 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(4):328-340

PubMed: 27987211 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Mol Cancer Res, 2017,

PubMed: 28289161 ( click the link to review the publication )

Endocrinology, 2017,

PubMed: 29028997 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(11):895-903

PubMed: 28696156 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )

J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )
PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )

Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103465-103476

PubMed: 29262576 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28002807 ( click the link to review the publication )

Hepatology, 2017, 66(6):2002-2015

PubMed: 28653763 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27196766 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(6):481-93

PubMed: 27185872 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(35):56826-56841

PubMed: 27472395 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

Mol Cancer, 2015,

PubMed: 26041671 ( click the link to review the publication )

J Bone Miner Res, 2015, 30(11):1959-68

PubMed: 25990470 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: 25485727 ( click the link to review the publication )

Mol Cancer Res, 2015,

PubMed: 26263910 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(17):2991-3004

PubMed: 26100015 ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )
PLoS One, 2015, 10(1):e0116895

PubMed: 25603314 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26515601 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )

Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Diabetes, 2013, 62(10):3448-58

PubMed: 23801577 ( click the link to review the publication )

BMC Cancer, 2013, 13:245

PubMed: 23688189 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )

Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Targets

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A4-Fuk	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMEK4NFYh\|ryP	MX;TRW5ITVJ?
KS-1	NEj3e3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHDfoxRUUN3ME2wMlA{QDN3IN88US=>	NF;3cW1USU6JRWK=
TE-11	Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrDTWM2OD1yLkC3PFIzKM7:TR?=	NHjwUm1USU6JRWK=
EW-1	NF;SVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwMEi1PFUh\|ryP	MWDTRW5ITVJ?
HMV-II	MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnniTWM2OD1yLkC4PFQ3KM7:TR?=	NY\a[lRjW0GQR1XS
COLO-205	NEHVUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMUC0OVQh\|ryP	NVHZW5p7W0GQR1XS
ES1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnOVWh{UUN3ME2wMlExPjl4IN88US=>	M17rRXNCVkeHUh?=
GDM-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTBwMUO2O\|Ih\|ryP	M{KxT3NCVkeHUh?=
ML-2	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHz1foRKSzVyPUCuNVU5QTZizszN	NUC0d2p1W0GQR1XS
Saos-2	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7pcGZKSzVyPUCuNVY2OjZizszN	NV3wNHB2W0GQR1XS
NCI-H1355	MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDJfmRNUUN3ME2wMlE5OTN3IN88US=>	NWn3WldDW0GQR1XS
G-401	Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn36TWM2OD1yLkG4NlMh\|ryP	NGDy[I9USU6JRWK=
EW-16	NYPYcY54T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jTXmlEPTB;MD6xPFc4PyEQvF2=	NGSwOIZUSU6JRWK=
EW-7	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlf2TWM2OD1yLkG4PFgyKM7:TR?=	MYTTRW5ITVJ?
NCI-H727	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMUm3PVQh\|ryP	NX3wWldsW0GQR1XS
LCLC-97TM1	NYjvb4NnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\EVndJUUN3ME2wMlIxQTV3IN88US=>	NIfZZ\|NUSU6JRWK=
NCI-H650	NF2zTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfwdlJCUUN3ME2wMlIyOzh2IN88US=>	NFzvZllUSU6JRWK=
NCI-H2122	NXvWWm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoG0TWM2OD1yLkKzNlk6KM7:TR?=	NF:4NW9USU6JRWK=
SK-N-DZ	NGHmVGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DodmlEPTB;MD6yN\|Y6QCEQvF2=	MV3TRW5ITVJ?
HT-29	NEjmRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LVNmlEPTB;MD6yOFI1QCEQvF2=	M2jqbnNCVkeHUh?=
LB771-HNC	M2PzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnlVY1KSzVyPUCuNlU6OTVizszN	NIjNUI9USU6JRWK=
HT-144	NUnWPGpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:4VmZKSzVyPUCuNlYyQTFizszN	M{PBdXNCVkeHUh?=
LAN-6	NFXXd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwMk[zOFgh\|ryP	M3\sWXNCVkeHUh?=
EW-18	NGnvU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPPdnpKSzVyPUCuNlcxODFizszN	NHnuO2pUSU6JRWK=
LS-1034	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LJN2lEPTB;MD6yO\|E{OiEQvF2=	NYHuXXdTW0GQR1XS
EW-11	NXrod29UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHNbmlKSzVyPUCuNlg1OzJizszN	MUHTRW5ITVJ?
SNU-C1	NFWwemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1z0OGlEPTB;MD6yPVMyOyEQvF2=	Mlv5V2FPT0WU
RS4-11	NXvBeFdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HqTmlEPTB;MD6zN\|c2QCEQvF2=	NHSzRmdUSU6JRWK=
ES4	NGHVNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPlOXRGUUN3ME2wMlQyODN6IN88US=>	NFPyN3pUSU6JRWK=
COLO-320-HSR	NYXhbFFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mli3TWM2OD1yLkSxN\|Y5KM7:TR?=	M3z1c3NCVkeHUh?=
NB10	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFuyVodKSzVyPUCuOFU1OzdizszN	NWfLOZl5W0GQR1XS
BFTC-905	MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwNE[3OVgh\|ryP	M3LTbnNCVkeHUh?=
A375	MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXm0dWwyUUN3ME2wMlQ4PjF5IN88US=>	MXjTRW5ITVJ?
SJRH30	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPmTWM2OD1yLkWwPFIzKM7:TR?=	M2\1ZXNCVkeHUh?=
NOS-1	NWniSId[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnztTWM2OD1yLkWyNlY4KM7:TR?=	NGXj[2tUSU6JRWK=
SIG-M5	M4rxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7m[WdyUUN3ME2wMlU{PTV5IN88US=>	M{To[XNCVkeHUh?=
DOK	NUP0Z4FvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHIPIt1UUN3ME2wMlU2PiEQvF2=	M3m2WXNCVkeHUh?=
NB69	NFz3[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwNUiyOVch\|ryP	NWe3U\|V7W0GQR1XS
SK-NEP-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXSTWM2OD1yLk[wNlM3KM7:TR?=	MoX5V2FPT0WU
SK-MM-2	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwNkW0PVEh\|ryP	MYrTRW5ITVJ?
NCI-H358	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLlTWM2OD1yLk[3NFgzKM7:TR?=	M3LMXnNCVkeHUh?=
RH-1	MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILpU45KSzVyPUCuO\|Q5PTlizszN	MWjTRW5ITVJ?
NH-12	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwN{[wOFYh\|ryP	M2rUXnNCVkeHUh?=
TE-12	Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTlTWM2OD1yLke2OFg3KM7:TR?=	Mon6V2FPT0WU
COLO-668	M1f5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEe4W2FKSzVyPUCuPFQ3PjZizszN	MnzWV2FPT0WU
PANC-08-13	NEn2VIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmToTWM2OD1yLki2N\|c4KM7:TR?=	M3KyOnNCVkeHUh?=
HCC2998	NWH2RlhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjzS3Y1UUN3ME2wMlg5OjZ\|IN88US=>	MlnUV2FPT0WU
ABC-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfUZmRSUUN3ME2wMlkxOzV{IN88US=>	M{DYPHNCVkeHUh?=
ES6	NIrCT\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;VeZV1UUN3ME2wMlkyODZ4IN88US=>	Ml;IV2FPT0WU
SNU-387	NUfm[pdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;UTWM2OD1yLkm5N\|k{KM7:TR?=	NVi4dHF5W0GQR1XS
CMK	NIfJ[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwOUm5Nlkh\|ryP	NWDaZVhrW0GQR1XS
SJSA-1	M1PaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TsN2lEPTB;MT6wN\|Y2OyEQvF2=	NW\EWFUxW0GQR1XS
SIMA	MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4GwOGlEPTB;MT6wOlgzPSEQvF2=	M{e5[3NCVkeHUh?=
ES3	MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTFwMUKyPVch\|ryP	MnHrV2FPT0WU
IGROV-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTFwMUW0OFQh\|ryP	NGnIN2VUSU6JRWK=
MEL-JUSO	NVu3eoduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjDTWM2OD1zLkG1O\|U6KM7:TR?=	NY\reVdjW0GQR1XS
T84	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\Kc2lEPTB;MT6yNFkyPCEQvF2=	M33CT3NCVkeHUh?=
CAL-85-1	NFfrbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF73S3ZKSzVyPUGuNlMyOzhizszN	MU\TRW5ITVJ?
RD	M{LWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\CTWM2OD1zLkK2OFU2KM7:TR?=	NWW3OJdCW0GQR1XS
TE-8	M{n2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTFwM{G0OlIh\|ryP	MUjTRW5ITVJ?
L-363	NVT2NppsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnmZXpKSzVyPUGuN\|QzODhizszN	NGm4clZUSU6JRWK=
EKVX	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoS0TWM2OD1zLkO0OVY5KM7:TR?=	NUTlb5JyW0GQR1XS
SK-MEL-3	M2TNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX71WHM5UUN3ME2xMlQ5PTV4IN88US=>	NFjBNIZUSU6JRWK=
TGBC24TKB	M{XqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTFwNUCxPVMh\|ryP	NF\TZYpUSU6JRWK=
NCI-H1770	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH65eoRKSzVyPUGuOVEyOTNizszN	NXjaWXR[W0GQR1XS
HuH-7	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\sTWM2OD1zLk[wNFk5KM7:TR?=	MkfvV2FPT0WU
HL-60	NG\ZbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrYNnV5UUN3ME2xMlY3QTJ6IN88US=>	MXnTRW5ITVJ?
TE-1	NWDTXJA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3:2RmlEPTB;MT63NFk1PSEQvF2=	MXHTRW5ITVJ?
LC-2-ad	M{DkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjtTWM2OD1zLkezPFg4KM7:TR?=	NUXZUFZIW0GQR1XS
LB647-SCLC	M332UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTFwN{[1PFMh\|ryP	MlPqV2FPT0WU
NCI-H2171	M{nxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV24Smo{UUN3ME2xMlc4PzF4IN88US=>	MYPTRW5ITVJ?
SK-PN-DW	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPlXJhKSzVyPUGuPVEzQThizszN	M2TidXNCVkeHUh?=
MC-IXC	M1u5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3P4fWlEPTB;MT65PFk5KM7:TR?=	MmrmV2FPT0WU
LS-513	NXn0cXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTOdVZVUUN3ME2yMlA2OzB3IN88US=>	MonSV2FPT0WU
EW-3	NWDwTG5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTJwMEm4OFQh\|ryP	NHLFTY1USU6JRWK=
OPM-2	NGn3NYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTJwMUCyJO69VQ>?	NGXJNmFUSU6JRWK=
LP-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTJwMkW4NFch\|ryP	M2\FZ3NCVkeHUh?=
LU-134-A	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTJwMke3JO69VQ>?	MmH1V2FPT0WU
CP66-MEL	Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTJwMkmwNVQh\|ryP	NVuwempyW0GQR1XS
HCC1143	M3r2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTJwNEWzOlgh\|ryP	Mmr1V2FPT0WU
LOXIMVI	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfQOpNKSzVyPUKuOlAzOSEQvF2=	MUTTRW5ITVJ?
TE-10	NX65PI9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXv[mt3UUN3ME2yMlcxQDN6IN88US=>	MXTTRW5ITVJ?
NCI-H1882	NXfjWoxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\LPYRYUUN3ME2yMlc2OjJ5IN88US=>	MnvmV2FPT0WU
CHP-126	NEjJZ\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPpZXpvUUN3ME2yMlc3OzF5IN88US=>	NXXBO3l4W0GQR1XS
NCI-H1623	NYrNU5Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTITnRqUUN3ME2yMlkzODJ2IN88US=>	M{DYS3NCVkeHUh?=
GB-1	M2jVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XKZWlEPTB;Mj65N\|QxPCEQvF2=	NXnIcW1sW0GQR1XS
RCC10RGB	M3TFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPYWlBsUUN3ME2yMlk2OjhzIN88US=>	MkDVV2FPT0WU
NCI-H2141	M1vFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vTe2lEPTB;Mj65Olg6PiEQvF2=	MkXNV2FPT0WU
GI-ME-N	NUH1NY91T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkWzTWM2OD1\|LkCwOVY2KM7:TR?=	MoTtV2FPT0WU
NCI-H526	NGfIVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfLPZVKSzVyPUOuNFQxQDVizszN	M4O5SHNCVkeHUh?=
NCI-H747	NWGx[YhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTNwMES5PVIh\|ryP	Ml;QV2FPT0WU
SNU-423	NY\yPWs1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnzPFR3UUN3ME2zMlIxOzF\|IN88US=>	MkfkV2FPT0WU
A427	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzzeHJKSzVyPUOuNlU3QTlizszN	MX\TRW5ITVJ?
CAL-12T	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LlOGlEPTB;Mz60NFcyOyEQvF2=	NVHrbYxIW0GQR1XS
LU-99A	NVu2PIVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLh[JRxUUN3ME2zMlQ4OTB3IN88US=>	NFiwXYxUSU6JRWK=
MS-1	M4jBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPNTWM2OD1\|LkWzOFI6KM7:TR?=	MmDaV2FPT0WU
SK-LU-1	MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XGOmlEPTB;Mz63OlI6PSEQvF2=	NWn5UlA3W0GQR1XS
SW837	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTNwN{[zN\|Mh\|ryP	MnPvV2FPT0WU
ES8	NIHh[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1:4fmlEPTB;Mz64N\|g4PyEQvF2=	NUTHfWdrW0GQR1XS
MZ2-MEL	NYDrfVNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvS[2FHUUN3ME2zMlkzODh4IN88US=>	MU\TRW5ITVJ?
TGW	NE\kNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGSxUINKSzVyPUSuNFE{OTFizszN	NYn1XZhQW0GQR1XS
GP5d	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHP[FRLUUN3ME20MlA2OzZ{IN88US=>	M2\QUXNCVkeHUh?=
BB49-HNC	MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7sN\|BKSzVyPUSuNVUzOTNizszN	NHLUd\|ZUSU6JRWK=
NB13	M3m0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHITWM2OD12LkK2PFg4KM7:TR?=	NVXKfo12W0GQR1XS
NTERA-S-cl-D1	M{XTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XyNmlEPTB;ND6yPFYyPSEQvF2=	MX7TRW5ITVJ?
NCI-H1648	M4n2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULMVJdSUUN3ME20MlI6QDF7IN88US=>	NIf5NVRUSU6JRWK=
LCLC-103H	M3nhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3y4NWlEPTB;ND6zNlE6PSEQvF2=	NH7X[mJUSU6JRWK=
LS-411N	NH3JXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDWUo9KSzVyPUSuOFQ5QDVizszN	MUPTRW5ITVJ?
NCI-H1092	NWHMRXlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTRwNEW2PFch\|ryP	MljmV2FPT0WU
PANC-10-05	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XTemlEPTB;ND62PVg1KM7:TR?=	Mn3lV2FPT0WU
DK-MG	NVrmeZFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXv0coxvUUN3ME20MlgxQTN\|IN88US=>	NUXXbVlNW0GQR1XS
OVCAR-5	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX64TGxrUUN3ME20MlgyOjJ4IN88US=>	Mmj2V2FPT0WU
CAL-39	NF7URVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\ETWM2OD12Lki3Olch\|ryP	M3vSUnNCVkeHUh?=
TE-441-T	NVX6epE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkP3TWM2OD12LkmwOVM4KM7:TR?=	NXfxdXo3W0GQR1XS
MOLT-16	NW\GNlV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjzXWxKSzVyPUSuPVUzPTNizszN	NIT5[3hUSU6JRWK=
MCF7	NHfsO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTVwMUS1NVch\|ryP	MkHEV2FPT0WU
CAPAN-1	NFOycW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{G3R2lEPTB;NT6yOVcxPyEQvF2=	NIfnfYVUSU6JRWK=
PSN1	NXnCfVZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTVwMkeyN\|Uh\|ryP	NWjDN2ZLW0GQR1XS
NCI-H292	MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVuzXlVNUUN3ME21MlMxODR2IN88US=>	MXzTRW5ITVJ?
CPC-N	NXXJPIdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4r3bGlEPTB;NT6zPVQyQSEQvF2=	NY\lTI9iW0GQR1XS
DoTc2-4510	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofETWM2OD13LkS1N\|cyKM7:TR?=	MlvuV2FPT0WU
LB1047-RCC	Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnGWpRNUUN3ME21MlU2QTN\|IN88US=>	MoX3V2FPT0WU
MHH-ES-1	NH30VVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrsbWJ[UUN3ME21MlU6QTB5IN88US=>	MleyV2FPT0WU
NMC-G1	M1TRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTVwN{CyNlch\|ryP	M2[4[XNCVkeHUh?=
SW1710	M2rvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHrTWM2OD13Lke0O\|UyKM7:TR?=	M170WnNCVkeHUh?=
YAPC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrJcGZKSzVyPUWuO\|YzODFizszN	MUfTRW5ITVJ?
22RV1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDXTJI1UUN3ME21MlgxODF7IN88US=>	NFTNN2RUSU6JRWK=
COLO-679	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUW1[Vh6UUN3ME21Mlg5QTR6IN88US=>	NITGUGpUSU6JRWK=
TCCSUP	M1vzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTVwOUOyOVkh\|ryP	MYDTRW5ITVJ?
C2BBe1	NV3McYdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTVwOUO5O{DPxE1?	MXfTRW5ITVJ?
TE-15	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXkdldKSzVyPU[uNFY3ODVizszN	MlTxV2FPT0WU
SCLC-21H	M{jnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\3TWM2OD14LkGwPFQ{KM7:TR?=	MmjlV2FPT0WU
EoL-1-cell	NXLrT\|NZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvqWodKSzVyPU[uNVY2PjNizszN	NWLlbZZGW0GQR1XS
NKM-1	NFrvV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFK0[mtKSzVyPU[uNVY4OSEQvF2=	MY\TRW5ITVJ?
NCI-H1304	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\IcoVKSzVyPU[uNlc1OjhizszN	M3PBSXNCVkeHUh?=
NB6	M3;xXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NESwd4dKSzVyPU[uNlk3OjJizszN	M3O3b3NCVkeHUh?=
NALM-6	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnO2TWM2OD14LkOzNlMh\|ryP	MXzTRW5ITVJ?
NCI-H522	NETM[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTZwM{OzNFYh\|ryP	M1OyVnNCVkeHUh?=
MV-4-11	NF\hWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfITWM2OD14LkO3NFc6KM7:TR?=	NUW3OJF{W0GQR1XS
LB2241-RCC	NX7mUZU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTZwM{i2Olch\|ryP	NHHRe4JUSU6JRWK=
NCI-H1417	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTZwNEC4OFch\|ryP	Mlu3V2FPT0WU
HT-1197	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULTOnFzUUN3ME22MlU4OTJ{IN88US=>	MW\TRW5ITVJ?
P30-OHK	MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7DV5BKSzVyPU[uOlI4PyEQvF2=	NF[4VVZUSU6JRWK=
ALL-PO	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1u2WmlEPTB;Nj63NVkyPiEQvF2=	NEDnVY9USU6JRWK=
OVCAR-4	NYq5VWcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MluyTWM2OD14Lke1OFA2KM7:TR?=	NVy4VGFCW0GQR1XS
HCC2157	NV;zWos4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLsTWM2OD14Lke3OFc2KM7:TR?=	NYW0bnAxW0GQR1XS
NCI-H838	M3H6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPFTWM2OD14Lkm2OFkh\|ryP	NFHhXGtUSU6JRWK=
NCI-H1299	MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TaZWlEPTB;Nj65O\|A6KM7:TR?=	NYPj[mx3W0GQR1XS
SW954	NXfHZmh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PMUGlEPTB;Nz6yNFA3QCEQvF2=	MmDkV2FPT0WU
NCI-H441	NH3RNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1KxSGlEPTB;Nz6zOFA3PSEQvF2=	MlTxV2FPT0WU
SK-MEL-2	NYLKSZpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYi2TYZnUUN3ME23MlQ5Ozd\|IN88US=>	Mnm4V2FPT0WU
KARPAS-45	NWLoTno3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTdwNkW5Nlkh\|ryP	M4jrTnNCVkeHUh?=
CAL-54	NHnWc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvtUmc{UUN3ME23MlgzQTd5IN88US=>	M13pWnNCVkeHUh?=
KYSE-180	NUi0ZVVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTdwOEi5OFEh\|ryP	NWHpXlJCW0GQR1XS
NCI-H187	MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTdwOUW5OFch\|ryP	NHzSOotUSU6JRWK=
RT-112	NXz5[44zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfHTWM2OD16LkC5Olc4KM7:TR?=	NHHpNWVUSU6JRWK=
NCI-H1437	M16wNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3[2SGlEPTB;OD6wPVc6PSEQvF2=	MmG3V2FPT0WU
SNU-449	NHzrfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PZc2lEPTB;OD6yPFI4OiEQvF2=	NEe5XXBUSU6JRWK=
HCC1187	NXe0TXRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYe2VWFpUUN3ME24MlI6OzlzIN88US=>	M1:zeHNCVkeHUh?=
NCI-H2030	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33CcmlEPTB;OD6zO\|cyPCEQvF2=	MXrTRW5ITVJ?
HuO-3N1	MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDpTWM2OD16LkO3PFQ1KM7:TR?=	M2jITnNCVkeHUh?=
COLO-792	NUTPTI5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4Pt[WlEPTB;OD60NVUzPyEQvF2=	MUXTRW5ITVJ?
MIA-PaCa-2	M1K0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLITWM2OD16Lki1OVA5KM7:TR?=	NXzVbGVxW0GQR1XS
SK-N-FI	NXfmdFRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjoe\|JKSzVyPUmuNFQzPSEQvF2=	MUjTRW5ITVJ?
MMAC-SF	Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvCenlKSzVyPUmuNFk4PTFizszN	M{nvfHNCVkeHUh?=
NCI-H28	NGX4RXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1m3PGlEPTB;OT6xNFQ3QSEQvF2=	NFn6[\|VUSU6JRWK=
ETK-1	M4Tr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTlwMkm5O\|Qh\|ryP	NHPDe2lUSU6JRWK=
NCI-H1993	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXtTWM2OD17LkS0NlYyKM7:TR?=	Mmn0V2FPT0WU
no-11	NXHBfYlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\tTWM2OD17LkS3NVIh\|ryP	MUDTRW5ITVJ?
ChaGo-K-1	NFi1fXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTlwNUG1PFMh\|ryP	MmLHV2FPT0WU
NCCIT	NHS4R5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\j[pN[UUN3ME25MlU{OTZ7IN88US=>	NHzuNlBUSU6JRWK=
SAS	NVvyVZZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInLfpVKSzVyPUGwMlI1QCEQvF2=	NVvFSI5qW0GQR1XS
A673	NV7kPZJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzkemNPUUN3ME2xNE4{PzB2IN88US=>	NGm5c2dUSU6JRWK=
NCI-H1522	NWC1[WdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXIRW5LUUN3ME2xNE4{PzB5IN88US=>	M{HGO3NCVkeHUh?=
NCI-H810	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4[wb2lEPTB;MUCuN\|kxPyEQvF2=	MnXkV2FPT0WU
IST-MES1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojRTWM2OD1zMD60OVY1KM7:TR?=	MnjSV2FPT0WU
GR-ST	MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXKUWpKSzVyPUGwMlUxOjRizszN	M4LaTXNCVkeHUh?=
SUP-T1	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPZOmI4UUN3ME2xNE44OzF5IN88US=>	MkXrV2FPT0WU
NB5	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHqXFI{UUN3ME2xNE46ODJ{IN88US=>	NXvOb5V3W0GQR1XS
MZ1-PC	NF3zU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoK0TWM2OD1zMD65OVcyKM7:TR?=	MYfTRW5ITVJ?
SK-CO-1	NGHmVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDWb2xKSzVyPUGwMlk6OzFizszN	NGnnc\|NUSU6JRWK=
Capan-2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEGxW2pKSzVyPUGxMlMyQThizszN	M2jnNHNCVkeHUh?=
697	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzHVpRTUUN3ME2xNU43PzV5IN88US=>	NWfHcXpmW0GQR1XS
REH	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\MTWM2OD1zMT63OFUyKM7:TR?=	M321UXNCVkeHUh?=
GI-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfIfGJKSzVyPUGxMlg3OTVizszN	M1vVNHNCVkeHUh?=
BB65-RCC	NW[1WXI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\sc2JKSzVyPUGyMlA6OTZizszN	MXXTRW5ITVJ?
NCI-H1651	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPwOYlKSzVyPUGyMlI1PzhizszN	NGLwXlRUSU6JRWK=
NCI-H1618	NUXyUFQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3jXGp6UUN3ME2xNk4{QTd4IN88US=>	MmPIV2FPT0WU
NCI-H2081	NHfzS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTF{Lk[xOFEh\|ryP	MkW2V2FPT0WU
GCIY	NXTI[2JqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVj1SoE3UUN3ME2xNk44OjF\|IN88US=>	Mkn1V2FPT0WU
NY	M3ixPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\4[XBKSzVyPUGzMlA3PDNizszN	NWLUTo85W0GQR1XS
PANC-03-27	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTF\|LkC4NFch\|ryP	NEPlXI5USU6JRWK=
BHY	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTF\|LkKxNlEh\|ryP	NXr5OJoyW0GQR1XS
SK-OV-3	M4ridmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHHTWM2OD1zMz6zO\|Y{KM7:TR?=	MknUV2FPT0WU
5637	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33OcmlEPTB;MUOuO\|c2QSEQvF2=	M4fjSnNCVkeHUh?=
LC-1F	NX\0RYtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTF2LkCzOVYh\|ryP	NFr0RWlUSU6JRWK=
SNB75	NFrORmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrpTWM2OD1zND6wN\|g{KM7:TR?=	M2DRdHNCVkeHUh?=
CHP-212	MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XUO2lEPTB;MUSuNFQ3PCEQvF2=	NVTUNIpWW0GQR1XS
HT-1376	NH61W2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2H5[mlEPTB;MUSuNVEzPiEQvF2=	MWnTRW5ITVJ?
MONO-MAC-6	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXOTZpKSzVyPUG0MlE2ODJizszN	MV3TRW5ITVJ?
CA46	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVqxNFlPUUN3ME2xOE4yQDJ5IN88US=>	MkTkV2FPT0WU
SCC-15	NUHEXm1KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTF2LkW1PFMh\|ryP	NXH2e5F2W0GQR1XS
ATN-1	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTrbXpKSzVyPUG0MlY3OjdizszN	MX7TRW5ITVJ?
NCI-H2405	NUHRO3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTF2LkixOVch\|ryP	NFrKc3VUSU6JRWK=
NCI-H716	M3;PV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\vcIhiUUN3ME2xOE45PDl\|IN88US=>	M3PXUHNCVkeHUh?=
SW620	M13uU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnr[mE4UUN3ME2xOE46ODF2IN88US=>	MoLXV2FPT0WU
NCI-H226	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTF2LkmwPFUh\|ryP	NITLTm9USU6JRWK=
SW962	NV7sfIhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzOTWM2OD1zND65OFMzKM7:TR?=	M{KxXHNCVkeHUh?=
KYSE-150	M2K2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrIU3RKSzVyPUG0Mlk2PSEQvF2=	MWfTRW5ITVJ?
OCUB-M	MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\wWpVKSzVyPUG0Mlk5QDNizszN	MUjTRW5ITVJ?
ES7	NHrqVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWe2WHhUUUN3ME2xOU4xQTh2IN88US=>	NVLMdYw6W0GQR1XS
SW1463	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkP6TWM2OD1zNT60NlI{KM7:TR?=	NV;HZ4FFW0GQR1XS
CAKI-1	NEHseoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37P[2lEPTB;MUWuOVM1PiEQvF2=	NETGRlNUSU6JRWK=
MKN28	NV3BbFFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XZc2lEPTB;MUWuOVQ4QSEQvF2=	MYPTRW5ITVJ?
SW13	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17pTWlEPTB;MUWuOlE5KM7:TR?=	NYXROIlxW0GQR1XS
A3-KAW	NH22dFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LwSGlEPTB;MUWuPVY6PyEQvF2=	NYX4U49JW0GQR1XS
LU-65	NYrhVog{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfieoRKSzVyPUG1Mlk4PjhizszN	NE\YXo9USU6JRWK=
Calu-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PPb2lEPTB;MU[uNFM3QCEQvF2=	MU\TRW5ITVJ?
ST486	NWfYW5BVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTKcHZFUUN3ME2xOk4xPDNzIN88US=>	MWXTRW5ITVJ?
BB30-HNC	MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoL4TWM2OD1zNj6xNlQ3KM7:TR?=	NYDMbWpVW0GQR1XS
EGI-1	NEC2eXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTF4LkS0OkDPxE1?	M{jjXXNCVkeHUh?=
SH-4	NXrXeYZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDoTWM2OD1zNj60O\|MyKM7:TR?=	MULTRW5ITVJ?
MN-60	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PWU2lEPTB;MUeuNlI6PyEQvF2=	NYnFN\|VuW0GQR1XS
MPP-89	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHi[XYyUUN3ME2xO{4zPDV7IN88US=>	M2jO[3NCVkeHUh?=
A2780	M{\4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGi3WGVKSzVyPUG3MlQyOzlizszN	MmfPV2FPT0WU
Daoy	MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXuOGdKSzVyPUG3MlQ3QTVizszN	NHS4VYxUSU6JRWK=
NCI-H2126	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoiyTWM2OD1zNz60O\|cyKM7:TR?=	NXiyN41TW0GQR1XS
NCI-H1563	NFjwc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDEOXpZUUN3ME2xO{41QTF5IN88US=>	MkHhV2FPT0WU
8-MG-BA	NFS5N2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTF5Lk[2OFgh\|ryP	Mn;4V2FPT0WU
786-0	M2q4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XScWlEPTB;MUeuPFM2OyEQvF2=	M3jTWXNCVkeHUh?=
AM-38	NVLDXGJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHKTWM2OD1zNz65N\|A3KM7:TR?=	MXrTRW5ITVJ?
COLO-824	M16zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFSxOHNKSzVyPUG4MlQ1OzZizszN	M3XXXXNCVkeHUh?=
SK-MEL-30	M13OdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYD4dY5SUUN3ME2xPE42ODh{IN88US=>	MWPTRW5ITVJ?
CESS	MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWn1UVVLUUN3ME2xPE44PjB7IN88US=>	MWXTRW5ITVJ?
BL-70	MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\5S3ZKSzVyPUG4MlgyPTZizszN	NXTkXZZZW0GQR1XS
NCI-H2170	NUGxSFJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTF6LkmxO\|kh\|ryP	NEPJO4NUSU6JRWK=
HT-3	MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnRNIlrUUN3ME2xPE46QDNizszN	NWHwW5RNW0GQR1XS
BOKU	NIjBSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TIOWlEPTB;MUmuNFM5OSEQvF2=	NH3l[VRUSU6JRWK=
HPAF-II	NWTvV202T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPhV3REUUN3ME2xPU4{ODF3IN88US=>	MYTTRW5ITVJ?
KGN	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGCwNG5KSzVyPUG5MlQ4PjVizszN	NV\aR5RyW0GQR1XS
MC-CAR	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\RWWFKSzVyPUG5MlY{OTNizszN	NI[4eI5USU6JRWK=
BHT-101	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fNb2lEPTB;MUmuO\|c4KM7:TR?=	MXnTRW5ITVJ?
SW1783	MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3RcHVYUUN3ME2xPU44QDB4IN88US=>	MX7TRW5ITVJ?
KP-N-YN	MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlH6TWM2OD1{MD6wNlYzKM7:TR?=	Mmq5V2FPT0WU
LU-165	NXXLWnh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHZTWM2OD1{MD61OVcyKM7:TR?=	M3L1OHNCVkeHUh?=
GOTO	Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fPVGlEPTB;MkCuOlQ2OSEQvF2=	M1jFN3NCVkeHUh?=
EFM-19	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2eyWGlEPTB;MkGuNFcyPiEQvF2=	M3ny[nNCVkeHUh?=
CTV-1	M{PKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTJzLkGwOVQh\|ryP	Mnv2V2FPT0WU
HEL	NUfrZog1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPqTWM2OD1{MT60NlE3KM7:TR?=	NFLLTlJUSU6JRWK=
SNU-C2B	M1vafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjuTWM2OD1{MT60NlYh\|ryP	NXTZXIlQW0GQR1XS
ECC4	NXjubIx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTJzLkewO{DPxE1?	M4m0e3NCVkeHUh?=
NEC8	Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTJzLkizOlgh\|ryP	Moe4V2FPT0WU
KMOE-2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXoZ2hKSzVyPUKxMlg6OjFizszN	NILOc4hUSU6JRWK=
NCI-H524	NEjrcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TDdmlEPTB;MkKuNFgxQCEQvF2=	MYPTRW5ITVJ?
WSU-NHL	NUHpVG5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2C2[GlEPTB;MkKuNVU4PyEQvF2=	NFzmO4VUSU6JRWK=
SF126	MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7ib4xbUUN3ME2yNk4zPDZ7IN88US=>	NWexU2V1W0GQR1XS
HOP-92	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\IT4VnUUN3ME2yNk4{OTZ5IN88US=>	MUfTRW5ITVJ?
CTB-1	MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlryTWM2OD1{Mj60Olc4KM7:TR?=	MkL5V2FPT0WU
KYSE-270	Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHuNoRUUUN3ME2yNk46OzV5IN88US=>	NX2xU2R3W0GQR1XS
SK-MEL-24	MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITnNpJKSzVyPUKzMlE5PyEQvF2=	M3SzOXNCVkeHUh?=
Calu-3	M1jS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mme4TWM2OD1{Mz6yNVI5KM7:TR?=	NEizO21USU6JRWK=
GAMG	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTJ\|LkKzOlch\|ryP	NIj2RZNUSU6JRWK=
SW1573	M373[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XhWGlEPTB;MkOuO\|QyPSEQvF2=	M4PqeXNCVkeHUh?=
MHH-NB-11	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVP6XWZLUUN3ME2yOE4xOTl2IN88US=>	MWLTRW5ITVJ?
TK10	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTJ2LkWwNVMh\|ryP	MUfTRW5ITVJ?
LB373-MEL-D	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jlTmlEPTB;MkSuOlA3PCEQvF2=	NXzadmltW0GQR1XS
KALS-1	M{ntTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXmUndKSzVyPUK0Mlc{OjdizszN	MX\TRW5ITVJ?
HUTU-80	NF;TVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPFXppKSzVyPUK1MlgxOzJizszN	Mkf4V2FPT0WU
HuP-T3	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInpOW9KSzVyPUK2MlE3PzRizszN	Mn36V2FPT0WU
OE19	NFTVeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTJ4LkKxOVMh\|ryP	NVnMbodLW0GQR1XS
J82	NXj3XlRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjYTWM2OD1{Nj6yOFcyKM7:TR?=	MkHoV2FPT0WU
DU-4475	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zQSWlEPTB;Mk[uN\|gyQSEQvF2=	M3raVXNCVkeHUh?=
DMS-53	NVLNT\|FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTJ4LkWxN\|gh\|ryP	MXPTRW5ITVJ?
COLO-741	M3[ydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlr2TWM2OD1{Nj64N\|Q1KM7:TR?=	MUjTRW5ITVJ?
SW48	NXjvRnJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\LdmhKSzVyPUK2Mlg5OiEQvF2=	MmXlV2FPT0WU
IGR-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzVR\|RKSzVyPUK2Mlk{OzRizszN	MX\TRW5ITVJ?
639-V	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTJ5LkCyOFUh\|ryP	MkjIV2FPT0WU
LK-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrTTWM2OD1{Nz60NVQyKM7:TR?=	NFzwUmVUSU6JRWK=
NCI-H2347	Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1r6c2lEPTB;MkeuPVY6QSEQvF2=	NVr3b\|FiW0GQR1XS
NCI-H2228	NHvycGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEG2bW1KSzVyPUK4MlA6ODVizszN	NWHs[YpSW0GQR1XS
LS-123	NYXWfnBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHZOJZDUUN3ME2yPE4yOjZ{IN88US=>	NUHSe\|ZtW0GQR1XS
U031	NXTyPYgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTJ6LkK1NkDPxE1?	NHfLb4dUSU6JRWK=
NCI-H1792	MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHX3U4xKSzVyPUK4MlQ4OjFizszN	NWrNTFNjW0GQR1XS
NCI-H2087	NFPLOYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33kb2lEPTB;MkiuO\|U2OiEQvF2=	MYjTRW5ITVJ?
NCI-H2342	MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTJ7LkWyNFgh\|ryP	Mn:zV2FPT0WU
SW626	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrUVolKSzVyPUK5Mlc2PiEQvF2=	NUSxVlA2W0GQR1XS
LB2518-MEL	NF;XbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHq3OmdKSzVyPUK5MlgyPSEQvF2=	NXS0OnVDW0GQR1XS
RXF393	NHq4R5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV6zTnlpUUN3ME2zNE4xQTV{IN88US=>	NUfJWYp5W0GQR1XS
LC4-1	NFOwb\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTNyLkOwPVIh\|ryP	NVXabZBjW0GQR1XS
NCI-H1694	NFfpfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PLOWlEPTB;M{CuOlYzPCEQvF2=	MlT3V2FPT0WU
K5	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\1TGpKSzVyPUOwMlk4ODJizszN	Mn;1V2FPT0WU
HDLM-2	M{GwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTTTWM2OD1\|MD65O\|I2KM7:TR?=	MYfTRW5ITVJ?
BCPAP	MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37jbmlEPTB;M{GuPFM4QSEQvF2=	MVTTRW5ITVJ?
BC-3	NUjRe2hXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLTTWM2OD1\|Mj6xOFA{KM7:TR?=	NEjUOXpUSU6JRWK=
LB996-RCC	M1T2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\ScGN6UUN3ME2zNk4zOzV6IN88US=>	MWLTRW5ITVJ?
NCI-H2009	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTN{LkS5PFEh\|ryP	MX3TRW5ITVJ?
HTC-C3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPZSWhDUUN3ME2zN{44PTF7IN88US=>	Ml7tV2FPT0WU
LAMA-84	MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP3eXZKSzVyPUO0MlQ1ODdizszN	MUjTRW5ITVJ?
CCRF-CEM	NXzxO\|gzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTN2LkW3NVUh\|ryP	NUfCbnI2W0GQR1XS
AN3-CA	NVHXZnhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIqyd2RKSzVyPUO1MlA2PjhizszN	MVrTRW5ITVJ?
NCI-H1734	NXjIN21TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\UWolPUUN3ME2zOU4zPTZzIN88US=>	MnLaV2FPT0WU
Ca-Ski	NUHUbG5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPpSFBKSzVyPUO1MlQyODFizszN	M2X5THNCVkeHUh?=
U-266	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHJZ2RSUUN3ME2zOU43OTF2IN88US=>	NH7LOpNUSU6JRWK=
SBC-5	MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjiTWM2OD1\|NT63O\|gyKM7:TR?=	NEj1XGxUSU6JRWK=
GT3TKB	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH21Z25KSzVyPUO3MlEyPSEQvF2=	NIPvfmdUSU6JRWK=
MDA-MB-175-VII	MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnDSVE{UUN3ME2zO{4zOjR6IN88US=>	M{HWXHNCVkeHUh?=
PFSK-1	M3z0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PTcWlEPTB;M{euNlQ{PSEQvF2=	M2D4bXNCVkeHUh?=
IMR-5	NEPVc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TDWWlEPTB;M{euNlQ5PyEQvF2=	MoWzV2FPT0WU
Daudi	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTN5LkO1PVch\|ryP	NHTTRY5USU6JRWK=
A498	NF[0NWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LlTmlEPTB;M{euO\|IyQCEQvF2=	NELRb3BUSU6JRWK=
SCC-4	NX[xNmp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHxTWM2OD1\|Nz63PFQ{KM7:TR?=	MXTTRW5ITVJ?
COLO-680N	NHjXN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVq1dVBmUUN3ME2zPE4zQDh3IN88US=>	MXvTRW5ITVJ?
SK-MES-1	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFi3N2hKSzVyPUO4MlMzOTVizszN	MWDTRW5ITVJ?
SR	NYHYdoNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjmT4NKSzVyPUO4MlU1QTVizszN	MoD3V2FPT0WU
LNCaP-Clone-FGC	M1nQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zLU2lEPTB;M{iuOVY{PyEQvF2=	MnzzV2FPT0WU
SK-HEP-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlGxTWM2OD1\|OD63PFIzKM7:TR?=	M{PFcHNCVkeHUh?=
BPH-1	NX\qd\|FbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3H3VGlEPTB;M{iuPFMzQSEQvF2=	M2n6XnNCVkeHUh?=
NCI-H1755	NFzyVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HDRWlEPTB;M{muOVgyPyEQvF2=	MXXTRW5ITVJ?
LXF-289	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjrTWM2OD1\|OT64NFg1KM7:TR?=	MnvnV2FPT0WU
SW1088	NVPZTZRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULwS\|R7UUN3ME20NE4zOTB5IN88US=>	NVW2V3lEW0GQR1XS
MOLT-4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HmcGlEPTB;NECuNlkxOSEQvF2=	NVvM[ZhpW0GQR1XS
AsPC-1	M{LUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHQfHRkUUN3ME20NE41PTh\|IN88US=>	M3mwUnNCVkeHUh?=
HOP-62	MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonXTWM2OD12MD62OVY5KM7:TR?=	NHnFSotUSU6JRWK=
A172	M2W2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvyTWM2OD12MD64OVEyKM7:TR?=	M4\JUnNCVkeHUh?=
SN12C	NUK5dlRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHVTIZpUUN3ME20NE46Ozh3IN88US=>	MkHQV2FPT0WU
MDA-MB-231	MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTRyLkm4PVgh\|ryP	NX[5dHBwW0GQR1XS
RPMI-2650	M1rybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTRzLkG1PVMh\|ryP	MYLTRW5ITVJ?
KYSE-140	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHKSW5KSzVyPUSxMlgyOjNizszN	NV:1bWlLW0GQR1XS
KINGS-1	M4CwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTR{LkS2PVch\|ryP	M{H0XXNCVkeHUh?=
HSC-3	NYPjWmNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTR{Lk[2OlEh\|ryP	MYPTRW5ITVJ?
PC-14	NXrhWWxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nmc2lEPTB;NEOuNVg5OiEQvF2=	M3PWN3NCVkeHUh?=
COR-L105	NF\LTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTR\|Lk[1NFIh\|ryP	MX\TRW5ITVJ?
BE-13	NWPtd\|VVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rGVmlEPTB;NESuNlM4OSEQvF2=	MWLTRW5ITVJ?
NCI-H661	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDYVXJkUUN3ME20OE4zQTV6IN88US=>	NIXhSWxUSU6JRWK=
IST-MEL1	NEfhPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFyzUGpKSzVyPUS0MlM2QTlizszN	NG\vfVlUSU6JRWK=
HCC1806	M1\S[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLVTWM2OD12ND61PFc{KM7:TR?=	MUnTRW5ITVJ?
COLO-800	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nsNWlEPTB;NESuPFQ2OyEQvF2=	NFTDeZpUSU6JRWK=
IST-SL2	MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrkfm9wUUN3ME20OU4yOjR5IN88US=>	NHTpXXlUSU6JRWK=
8305C	NHXvZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7uTWM2OD12NT6zNFkh\|ryP	MYjTRW5ITVJ?
UACC-62	M3r6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1m0[GlEPTB;NE[uNlg4PSEQvF2=	NWCyUYxzW0GQR1XS
COR-L23	NVXlfIRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPsboZwUUN3ME20O{4yQTlizszN	NHzjUWNUSU6JRWK=
EFE-184	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTR5LkO4PEDPxE1?	NWf0cI5OW0GQR1XS
DMS-114	M4DrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDv[GJKSzVyPUS3MlQyPDlizszN	Mn21V2FPT0WU
KYSE-520	NFTCZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TF[2lEPTB;NEiuOVMyPSEQvF2=	MkW2V2FPT0WU
SNG-M	NWPlbpB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\ne2lEPTB;NEmuOFM1KM7:TR?=	MUXTRW5ITVJ?
A2058	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTR7LkS4PFUh\|ryP	NIjafYZUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the V_max is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. ^[1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log₁₀ compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerPro^TM Kinase Selectivity Assay Kit.
Cell Research:^[1]	- Collapse Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells Concentrations: 0.02-0.8 μM Incubation Time: 3 days Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model Dosages: 25 mg / kg and 75 mg / kg Administration: Orally administrated at once-daily oral dose for 14 days (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Linsitinib (OSI-906) SDF

Molecular Weight	421.49
Formula	C₂₆H₂₃N₅O
CAS No.	867160-71-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02546544	Completed	Drug: Linsitinib	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01672736	Terminated	Drug: ASP7487 Velcade Dexamethasone	Multiple Myeloma	University Health Network Toronto\|Multiple Myeloma Research Consortium\|Astellas Pharma Inc	September 2012	Phase 1\|Phase 2
NCT01529684	Completed	Drug: radio-labeled OSI-906\|Drug: OSI-906	Advanced Solid Tumors\|Pharmacokinetics of 14C-OSI-906	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	March 19 2012	Phase 1
NCT01221077	Completed	Drug: OSI-906\|Drug: Erlotinib\|Drug: Placebo	NSCLC\|Non Small Cell Lung Cancer	Astellas Pharma Inc	April 8 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
Answer:
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Pan IGF-1R Inhibitor

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
Most Potent IGF-1R Inhibitor

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
IGF-1R Inhibitor in Clinical Trial

BMS-754807 : Phase II for Breast Cancer.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). Picropodophyllin (PPP) induces apoptosis with antineoplastic activity.
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 (CS-0117) is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 (GSK 552602A) is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
GSK1904529A

GSK1904529A (GSK 4529) is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
BMS-754807

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Features:Muti-inhibitor of the IGR-1R/IR family.
AG-1024

AG-1024 (Tyrphostin, AGS 200) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)